TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15581197

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 780

Group type: COMPARATOR
Intervention: Inhaled salbutamol
Number of subjects: 780
Study: 11049910

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of fluvoxamine and erythromycin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8994706

Group type: EXPERIMENTAL
Intervention: HPCD (hemostatic puncture closure device)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100
Study: 1732133

Group type: EXPERIMENTAL
Intervention: Electrohydraulic lithotripter (MPL 9000; 16, 20, and 24 kV)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electromagnetic lithotripter (Lithostar Plus; settings 5, 7, and 9)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Piezoelectric lithotripter (Piezolith 2300; settings 2, 3, and 4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Visual analogue scale
Number of subjects: 9

Group type: COMPARATOR
Intervention: McGill Pain Questionnaire
Number of subjects: 9

Group type: COMPARATOR
Intervention: Somatosensory evoked potentials
Number of subjects: 9
Study: 2485273

Group type: COMPARATOR
Intervention: Fibrinogen derivatives and platelet activation products in patients with fulminant hepatic failure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Heparinization before haemoperfusion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resin and charcoal haemoperfusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fibrinogen derivatives and platelet activation products in patients with compensated chronic liver disease
Number of subjects: 31
Study: 31012513

Group type: EXPERIMENTAL
Intervention: Current flare status assessment (urological or pelvic pain symptoms that are much worse than usual)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Pelvic pain and urological symptoms during flares
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Flare duration assessment
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Adjusted analyses of flare risk factors
Number of subjects: 385
Study: 28748081

Group type: EXPERIMENTAL
Intervention: 225 μg iodine as potassium iodide capsule daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: 450 g of appropriately iodized salt (30‐40 μg I as KIO3/g of salt) weekly for household consumption for 6 months
Number of subjects: 0
Study: 24973337

Group type: EXPERIMENTAL
Intervention: Vowel auditory training for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 23585292

Group type: EXPERIMENTAL
Intervention: Low caloric preload with consistent calorie information
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High caloric preload with consistent calorie information
Number of subjects: 4

Group type: COMPARATOR
Intervention: High caloric preload
Number of subjects: 4
Study: 21196441

Group type: COMPARATOR
Intervention: CHOP-21
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: CHOP-14
Number of subjects: 323
Study: 19218540

Group type: EXPERIMENTAL
Intervention: Intensified extended dialysis (IED) therapy, dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard dialysis (SED) therapy, dosed to maintain plasma urea levels between 120 and 150 mg/dL (20‐25 mmol/L)
Number of subjects: 156
Study: 17123910

Group type: EXPERIMENTAL
Intervention: Therapeutic jaw exercises (n = 25)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 55
Study: 15622365

Group type: EXPERIMENTAL
Intervention: Practice (30-60 minute proctored session)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No practice
Number of subjects: 29
Study: 11376910

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.5 mg/kg bolus followed by 0.25 mg/kg per h (group 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No ketamine (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.25 mg/kg bolus followed by 0.125 mg/kg per h (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 0.25 mg/kg and 0.125 mg/kg per h (group 4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 0.5 mg/kg and 0.25 mg/kg per h (group 5)
Number of subjects: 100
Study: 9425677

Group type: EXPERIMENTAL
Intervention: Phonological priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Legal nonwords
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudohomophone foils
Number of subjects: 0
Study: 7683942

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (intravenous leucovorin 200 mg/m2/day, 5-fluorouracil 550 mg/m2/day, cisplatin 20 mg/m2/day for four week cycles)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 40
Study: 3828169

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia (100 micrograms/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced type of fentanyl anaesthesia (5 micrograms/kg)
Number of subjects: 0
Study: 30735063

Group type: EXPERIMENTAL
Intervention: External focus (concentration on the ball) in experiment 1
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: External focus (focus on the platform) in experiment 2
Number of subjects: 63

Group type: COMPARATOR
Intervention: Internal focus (concentration on inside of the foot) in experiment 1
Number of subjects: 63

Group type: COMPARATOR
Intervention: Internal focus (focus on the feet) in experiment 2
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no focus instructions) in both experiments
Number of subjects: 63
Study: 29914482

Group type: EXPERIMENTAL
Intervention: RACIPE computational tool for modeling gene regulatory circuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coupled toggle-switch circuits and a published circuit of B-lymphopoiesis
Number of subjects: 0
Study: 26602782

Group type: EXPERIMENTAL
Intervention: Daily sedation interruption plus protocolized sedation (DSI + PS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Protocolized sedation only (PS)
Number of subjects: 129
Study: 25544955

Group type: EXPERIMENTAL
Intervention: 1 mL of ketamine plus 2 mL of bupivacaine 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mL of normal saline plus 2 mL of bupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mL of normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 60
Study: 22240782

Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin (GP)
Number of subjects: 433

Group type: COMPARATOR
Intervention: gemcitabine-vinorelbine (N)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: gemcitabine-ifosfamide-cisplatin (triplet)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: gemcitabine-ifosfamide-vinorelbine (triplet)
Number of subjects: 433

Group type: COMPARATOR
Intervention: P-containing therapy
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: triplets
Number of subjects: 433

Group type: COMPARATOR
Intervention: P-containing regimens
Number of subjects: 433
Study: 21055287

Group type: EXPERIMENTAL
Intervention: Prehospital ECG (Group B)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Prehospital ECG and early telephonic notification (Group C)
Number of subjects: 506

Group type: COMPARATOR
Intervention: No prehospital ECG (Group A)
Number of subjects: 506
Study: 18681997

Group type: EXPERIMENTAL
Intervention: 5% oxygen
Number of subjects: 1916

Group type: COMPARATOR
Intervention: 20% oxygen
Number of subjects: 1916
Study: 15933509

Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotics
Number of subjects: 7
Study: 12075761

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Penicillin V (100,000 IU/kg/day in three divided doses for 10 days)
Number of subjects: 292
Study: 9534082

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study: 7636641

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (no calcium)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate) in black subjects
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate) based on baseline calcium intake quartiles
Number of subjects: 101
Study: 2651327

Group type: EXPERIMENTAL
Intervention: Oral vasodilators
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Long-term survival
Number of subjects: 16
Study: 336116

Group type: EXPERIMENTAL
Intervention: Schedule I: Prednisone plus chlorambucil (CLB) given as a once-a-month dose of 0.4-0.8 mg/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Schedule II: Prednisone plus chlorambucil (CLB) given as a daily dose of 0.08 mg/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Schedule III: Prednisone alone
Number of subjects: 96
Study: 27633965

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (arm B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 46
Study: 26024005

Group type: EXPERIMENTAL
Intervention: Double tunnels technique (DTT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard open decompression of the median nerve (control)
Number of subjects: 220
Study: 23860024

Group type: EXPERIMENTAL
Intervention: Naturopathic reflex therapies (massage, Gua Sha massage, cupping, wet packs, rhythmic embrocation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturopathic reflex therapies
Number of subjects: 0
Study: 21466516

Group type: EXPERIMENTAL
Intervention: Four-step multidisciplinary antenatal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard obstetric antenatal care
Number of subjects: 0
Study: 19197206

Group type: EXPERIMENTAL
Intervention: Vibration (1.2 mm, 65 Hz) during exercise with 40% 1RM load
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vibration (1.2 mm, 65 Hz) during exercise with 70% 1RM load
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham vibration during exercise with 40% 1RM load
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham vibration during exercise with 70% 1RM load
Number of subjects: 11
Study: 16439927

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 15526716

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Before treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: After treatment
Number of subjects: 12
Study: 11091828

Group type: EXPERIMENTAL
Intervention: Topical ethanol applied to the operative site for three minutes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline applied to the operative site for three minutes (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups received the same analgesic protocol including infiltration of the operative site with ropivacaine
Number of subjects: 64
Study: 9372359

Group type: EXPERIMENTAL
Intervention: Allylamine preparations and ciclopirox olamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxiconazole, econazole, and 2.5% hydrocortisone
Number of subjects: 0
Study: 1403038

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 25 mg/m2/d times three, intravenous (IV) bolus plus cisplatin (CDDP) 100 mg/m2, 24 hour infusion, every 3 weeks times six; preceded by high-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four.
Number of subjects: 198

Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four, followed by Doxorubicin (DOX) and Cisplatin (CDDP).
Number of subjects: 198
Study: 3925888

Group type: EXPERIMENTAL
Intervention: Protocol I (OK‐432 group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Protocol II (non‐OK‐432 group)
Number of subjects: 45
Study: 31593709

Group type: EXPERIMENTAL
Intervention: 7.5 mg i.v. citalopram
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 11.25 mg citalopram
Number of subjects: 32

Group type: COMPARATOR
Intervention: Citalopram (both dosages)
Number of subjects: 32
Study: 30873908

Group type: EXPERIMENTAL
Intervention: Symptom cluster (depression, anxiety, fatigue, impaired sleep quality)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 302
Study: 27723546

Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional vocational rehabilitation (TVR)
Number of subjects: 61
Study: 25751386

Group type: EXPERIMENTAL
Intervention: Oral solution group (treatment group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Regular diet group (control group)
Number of subjects: 78
Study: 23245621

Group type: EXPERIMENTAL
Intervention: Carvedilol 2.5mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Carvedilol 20mg
Number of subjects: 364

Group type: COMPARATOR
Intervention: Optimal standard therapy
Number of subjects: 364
Study: 21676008

Group type: EXPERIMENTAL
Intervention: Pharmacobehavioral treatment
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 321
Study: 17672828

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) using recombinant human ASB (rhASB)
Number of subjects: 4
Study: 16394784

Group type: EXPERIMENTAL
Intervention: Prone position intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (supine position)
Number of subjects: 0
Study: 14959954

Group type: EXPERIMENTAL
Intervention: Bisphosphonate infusion (pamidronate or clodronate)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no bisphosphonate)
Number of subjects: 25
Study: 11000340

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 518
Study: 8678396

Group type: EXPERIMENTAL
Intervention: Electrical and pharmacologic cardioversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic regimens for recent onset atrial fibrillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin vs Aspirin in patients older than 75 years
Number of subjects: 0
Study: 1363497

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6693580

Group type: EXPERIMENTAL
Intervention: lorazepam infusion at two different rates
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 10
Study: 2877644

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol (100 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone (50 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapy with chlorthalidone
Number of subjects: 0
Study: 31362691

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0
Study: 29877114

Group type: EXPERIMENTAL
Intervention: State anxiety induction
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Participants with SAD
Number of subjects: 129

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 129
Study: 28152655

Group type: EXPERIMENTAL
Intervention: del Nido (DN) solution
Number of subjects: 59

Group type: COMPARATOR
Intervention: modified St. Thomas' (MST) cardioplegia solution
Number of subjects: 59
Study: 26081016

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional open surgery (TOS)
Number of subjects: 122
Study: 23870447

Group type: EXPERIMENTAL
Intervention: Spatial training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Perceptual training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-endurance training
Number of subjects: 33
Study: 20198403

Group type: EXPERIMENTAL
Intervention: SmartSet HV
Number of subjects: 35

Group type: COMPARATOR
Intervention: Palacos R
Number of subjects: 35
Study: 18197917

Group type: EXPERIMENTAL
Intervention: CXR changes in the exacerbation group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CXR changes in the spirometric decline group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between FVC or FEV(1) and profusion score
Number of subjects: 36
Study: 16458984

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling on an ergometric cycle 3 times a week for 30 min for 3 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (continued as they did previously)
Number of subjects: 17
Study: 12743862

Group type: EXPERIMENTAL
Intervention: VasoSeal
Number of subjects: 57

Group type: COMPARATOR
Intervention: Compressar
Number of subjects: 57
Study: 11029345

Group type: EXPERIMENTAL
Intervention: pH-corrected group (THAM administered)
Number of subjects: 12

Group type: COMPARATOR
Intervention: pH-uncorrected group (no THAM administered)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 8816034

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no additional iron treatment)
Number of subjects: 100
Study: 1486738

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day) and 500 mg of calcium
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day) continued for a third year
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day)
Number of subjects: 36
Study: 6535849

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study: 30865304

Group type: EXPERIMENTAL
Intervention: Preventure program (cognitive behavioral therapy-based group sessions targeting personality risk profiles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventure program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28768270

Group type: EXPERIMENTAL
Intervention: Asthma education sessions attended by 61 patients (27%)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Asthma education sessions not attended (non-attenders)
Number of subjects: 223
Study: 25576014

Group type: EXPERIMENTAL
Intervention: Enhanced recruitment (ER) strategy including personalized outreach, matching parent preferences, and community endorsement
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard recruitment (invitation by mail)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Enhanced recruitment (ER) strategy
Number of subjects: 256
Study: 23415907

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) in combination with methotrexate (MTX 10 mg/week) and leflunomide (LEF 20 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (MTX 10 mg/week plus LEF 20 mg/day without TGP)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP)
Number of subjects: 204
Study: 21194310

Group type: EXPERIMENTAL
Intervention: Lean women with PCOS (BMI <25 kg/m²)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nonlean subjects (BMI ≥28 kg/m²)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 78
Study: 19875763

Group type: EXPERIMENTAL
Intervention: Counseling intervention (6-month, 14-session)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 17061632

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 2 mg/kg with clonidine 2 microg/kg (group BUP+CLO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.125% bupivacaine 2 mg/kg (group BUP)
Number of subjects: 30
Study: 14722164

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 10
Study: 11499408

Group type: EXPERIMENTAL
Intervention: Presence of 3 amino-acid substitutions (His275Gln, Gly281Ala, His299Gln) and kappa repeat region
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: cg2 gene mutations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 3 codons and kappa repeat region
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: kappa repeat region
Number of subjects: 53
Study: 9710396

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in 66% nitrous oxide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in oxygen
Number of subjects: 51

Group type: COMPARATOR
Intervention: 5% halothane in 66% nitrous oxide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 51
Study: 8273728

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2915010

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manipulation and plaster
Number of subjects: 50